Sernova and Seraxis plan merger to form BetaNova Biotherapeutics

Sernova and Seraxis plan to merge their type 1 diabetes islet cell replacement programs into BetaNova Biotherapeutics in 2026.

Samsung Biologics publishes offer prospectus for PolyPeptide

Samsung Biologics has published the offer prospectus for PolyPeptide, with the main tender period expected from September 15 to October 12, 2026.

Valerio Therapeutics signs agreement to acquire Etherna

Valerio Therapeutics plans to acquire Etherna at a €30 million enterprise value and funds the deal with a €40.25 million PIPE financing.

BioMarin to acquire Alesta for HPP candidate ALE1

BioMarin will acquire Alesta Therapeutics to add ALE1, an oral Phase 1/2a candidate for hypophosphatasia, to its pipeline.

Moderna reports positive Phase 3 melanoma data

Moderna reported positive Phase 3 topline data for intismeran autogene plus pembrolizumab in adjuvant melanoma treatment.

From Anonymous Clicks to Connected HCP Journeys: Why Integrated SSO Matters in Pharma Marketing

Statutory reimbursement for cannabis flower ends without transition period

Germany's statutory reimbursement for cannabis flower ended on 30 July. An industry initiative seeks transition rules for ongoing therapies.

GSK plans new global R&D centre in Cambridge

GSK will invest £400 million in a new Cambridge R&D centre and shift UK research operations from Stevenage by 2029.

Bausch + Lomb highlights two product launches

Bausch + Lomb highlights two launches: a vitrectomy cutter for Europe and preservative-free lubricant eye drops in the United States.

argenx to acquire Forte Biosciences and expand immunology pipeline

argenx plans to acquire Forte Biosciences and add FB102, a first-in-class anti-CD122 antibody, to its immunology pipeline.

LINDA AG launches first OTC private-label medicine with ibuprofen

LINDA AG is introducing Ibuprofen 400 mg as the first OTC medicine under its own pharmacy brand across LINDA Premium pharmacies.

Lilly to acquire AtaiBeckley and expand depression pipeline

Lilly plans to acquire AtaiBeckley, adding clinical neuroplastogen programs for treatment-resistant depression to its neuroscience pipeline.

Schwabe takes majority stake in Hydraid

Schwabe Group takes a majority stake in Hydraid, strengthening its position in natural health solutions and functional sports hydration.

Besins acquires UniD to expand pharmatech capabilities

Besins Healthcare acquires Belgium-based UniD Manufacturing to expand long-acting drug delivery and hormone health innovation capabilities.

Vertex to buy Crinetics for about $10 billion

Vertex will acquire Crinetics for about $10 billion, adding PALSONIFY and late-stage endocrine disease assets to its portfolio.

DAT 2026: Final agenda for Munich published

The final agenda for German Pharmacists’ Day 2026 has been published. The event will take place in Munich in September.

Merz visits Sandoz site in Barleben

German Chancellor Friedrich Merz visits Sandoz in Barleben, highlighting medicine supply, value creation and stable policy conditions.

Otsuka completes acquisition of Transcend Therapeutics

Otsuka America has completed its acquisition of Transcend Therapeutics, adding a late-stage PTSD candidate to its CNS pipeline.

Bayer Kultur reviews stARTfestival 2026

Bayer Kultur has closed stARTfestival 2026. Around 30 events combined international artists, dance, performance and talent development.

STADA to acquire Orifarm consumer healthcare portfolio

STADA will acquire 16 VMS brands from Orifarm, expanding its consumer healthcare footprint in Europe, especially Nordics, Belgium and Poland.